Parkinson's disease affects over **10 million people worldwide**. It is progressive, incurable, and driven by a complex web of interconnected molecular failures — the toxic accumulation of a protein called **alpha-synuclein**, disrupted lysosomal waste-clearing, mitochondrial dysfunction, and the gradual death of dopamine-producing neurons.
The challenge for researchers has always been that Parkinson's isn't one broken pathway. It's many. A drug that fixes one mechanism often misses the others. Which is why the new findings published on **March 16, 2026**, in the *Journal of Clinical Investigation* by scientists at **Northwestern Medicine** are particularly striking.
They've found that a single compound — already FDA-approved, already proven safe in humans — can simultaneously target **multiple** of those broken pathways at once.
**The Compound: NALL**
**N-acetyl-L-leucine (NALL)** is an amino acid derivative of leucine, one of the branched-chain amino acids. It has been used for decades in Europe and other parts of the world to treat **acute vertigo and vestibular disorders** — conditions affecting balance and the inner ear.
In 2024, NALL received **FDA approval** for a rare genetic condition called **Niemann-Pick disease type C1**, a progressive neurological disorder. The approval established NALL's safety profile in humans — a critical foundation for exploring other potential uses.
Recent research had suggested NALL might have neuroprotective effects in Parkinson's disease. But the *mechanisms* — exactly why and how it might work — were unknown. That's what the Northwestern team set out to discover.
**What the Scientists Did**
The research team, led by co-corresponding authors **PingPing Song, PhD**, research associate professor in Northwestern's Davee Department of Neurology, and **Dimitri Krainc, MD, PhD**, chair and Aaron Montgomery Ward Professor of Neurology, took a sophisticated multi-pronged approach.
First, they created **dopaminergic neurons** — the specific type of nerve cells that die in Parkinson's disease — from **induced pluripotent stem cells (iPSCs)** derived from patients with both familial and sporadic forms of Parkinson's. This is a cutting-edge model that lets scientists study actual Parkinson's disease biology in a dish, using cells carrying the same genetic variants as real patients.
They then treated these patient-derived neurons with NALL and conducted comprehensive biochemical and molecular analyses to identify exactly which pathways changed.
Finally, they validated their findings in **live animal models** — mice with LRRK2-mutant Parkinson's disease, one of the most common genetic forms — administering NALL orally and evaluating its effects on both molecular markers and **dopamine-dependent motor behaviour** (the physical movement impairments that define Parkinson's in patients).
**What They Found**
NALL simultaneously affected **multiple key pathways** implicated in Parkinson's disease:
🧬 **Alpha-synuclein pathology** — NALL reduced the toxic aggregation of alpha-synuclein, the protein whose clumping is one of the hallmarks of Parkinson's disease ⚙️ **Lysosomal function** — NALL improved the cellular waste-clearing system that normally removes damaged proteins; in Parkinson's, this system is often overwhelmed 🔋 **Mitochondrial proteins** — NALL showed beneficial effects on mitochondrial function, addressing one of the key energy-failure mechanisms in Parkinson's 🧠 **Synaptic function** — NALL improved synaptic communication between neurons, relevant to the cognitive and motor symptoms of the disease 🐭 **Motor behaviour in mice** — In the animal models, oral NALL treatment improved dopamine-dependent motor learning behaviour — the mice moved better
"This work demonstrates that NALL can influence several Parkinson's disease-relevant pathways, including alpha-synuclein pathology, synaptic function, lysosomal pathways and mitochondrial proteins, suggesting broader relevance for neurodegeneration," said Dr. Song.
**Why This Is Significant**
The fact that NALL touches *multiple* Parkinson's pathways simultaneously is what makes this particularly interesting. Most drugs for neurodegenerative diseases are designed to hit one target. But Parkinson's is a disease of convergent failures — which is partly why single-target approaches have had limited success.
A compound that addresses alpha-synuclein buildup *and* lysosomal clearance *and* mitochondrial health *and* synaptic function in the same treatment changes the calculus significantly.
Equally important: NALL is **already FDA-approved and has a known human safety profile**. It crosses the blood-brain barrier. It's taken orally. These are not trivial advantages — many promising compounds fail not because they don't work biologically, but because they can't safely reach the brain or are poorly tolerated.
NALL has cleared those hurdles for other conditions. The path to a Parkinson's clinical trial is therefore considerably shorter than it would be for a brand-new compound starting from scratch.
**What Comes Next**
This is a preclinical study — the findings are in patient-derived cells and mouse models, not in human Parkinson's patients. The translational leap to clinical trials requires further safety testing and regulatory planning.
But the combination of a clear multi-pathway mechanism, a known-safe compound, and significant animal model results creates a compelling basis for clinical investigation. The research team is expected to pursue human trial design as the next step.
For the more than **10 million people living with Parkinson's disease globally** — and the researchers who have spent careers fighting it — today's publication is exactly the kind of signal that precedes progress. 🧬💊
*Sources: Northwestern Medicine / Feinberg School of Medicine (March 16, 2026) · The Journal of Clinical Investigation · PingPing Song, PhD · Dimitri Krainc, MD, PhD · FDA NALL approval (Niemann-Pick disease type C1, 2024)*
